Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn

Background: Transient tachypnea of the newborn [TTN] is a common physiologic lung disorder. Stimulation of β-adrenergic receptors could alleviate the condition. Aim of the work: The study was undertaken to assess the efficacy and safety of inhaled salbutamol in reduction of TTN, oxygen treatment an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ahmed Salama, Lotfy El-Seheimy, Mohamed Elsamanoudy
Formato:	article
Lenguaje:	EN
Publicado:	Al-Azhar University, Faculty of Medicine (Damietta) 2020
Materias:	neonate salbutamol transient tachypnea nebulized Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/09c70ed0e3ff40c9b7fae27b3e46ff95
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:09c70ed0e3ff40c9b7fae27b3e46ff95
record_format	dspace
spelling	oai:doaj.org-article:09c70ed0e3ff40c9b7fae27b3e46ff952021-12-02T13:52:45ZInhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn2636-41742682-378010.21608/ijma.2020.21436.1064https://doaj.org/article/09c70ed0e3ff40c9b7fae27b3e46ff952020-04-01T00:00:00Zhttps://ijma.journals.ekb.eg/article_82669_e29116444c14842204ac087030cc7dcc.pdfhttps://doaj.org/toc/2636-4174https://doaj.org/toc/2682-3780Background: Transient tachypnea of the newborn [TTN] is a common physiologic lung disorder. Stimulation of β-adrenergic receptors could alleviate the condition. Aim of the work: The study was undertaken to assess the efficacy and safety of inhaled salbutamol in reduction of TTN, oxygen treatment and hospitalization. Patients and Methods:This clinical study included 150 [50 control group, 50 single dose of salbutamol and 50 double-doses of salbutamol] infants between 35th-39th week's gestation. Inhaled salbutamol was given and comparison between the three groups was carried out. Results: Treatable and control groups were comparable as regard neonatal and maternal characteristics. Heart rate was significantly increased in group B when compared to control group half and one hour after treatment. In addition, respiratory rate was significantly increase in group B when compared to group A at half hour after treatment and continued till 8 hours after treatment. The TTN score after treatment was significantly lower in group B when compared to group A at one hour after nebulized salbutamol and continued till 8 hours. Furthermore, time before initiation of feeding was significantly reduced in group B when compared to group A [26.72[±3.68] vs [39.66[±4.7] and also there was significant reduction of hospitalization days in group B when compared to group A [3.78 [±1.25] vs [7.36[±1.28]. Conclusion: Inhalational salbutamol reduced duration of supplemental oxygen therapy, the duration of hospitalization and time before initiation of feeding, and no adverse effects were reported. Thus, inhaled salbutamol seems to be effective and safe in TTN.Ahmed SalamaLotfy El-SeheimyMohamed ElsamanoudyAl-Azhar University, Faculty of Medicine (Damietta)articleneonatesalbutamoltransienttachypneanebulizedMedicine (General)R5-920ENInternational Journal of Medical Arts, Vol 2, Iss 2, Pp 457-461 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	neonate salbutamol transient tachypnea nebulized Medicine (General) R5-920
spellingShingle	neonate salbutamol transient tachypnea nebulized Medicine (General) R5-920 Ahmed Salama Lotfy El-Seheimy Mohamed Elsamanoudy Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn
description	Background: Transient tachypnea of the newborn [TTN] is a common physiologic lung disorder. Stimulation of β-adrenergic receptors could alleviate the condition. Aim of the work: The study was undertaken to assess the efficacy and safety of inhaled salbutamol in reduction of TTN, oxygen treatment and hospitalization. Patients and Methods:This clinical study included 150 [50 control group, 50 single dose of salbutamol and 50 double-doses of salbutamol] infants between 35th-39th week's gestation. Inhaled salbutamol was given and comparison between the three groups was carried out. Results: Treatable and control groups were comparable as regard neonatal and maternal characteristics. Heart rate was significantly increased in group B when compared to control group half and one hour after treatment. In addition, respiratory rate was significantly increase in group B when compared to group A at half hour after treatment and continued till 8 hours after treatment. The TTN score after treatment was significantly lower in group B when compared to group A at one hour after nebulized salbutamol and continued till 8 hours. Furthermore, time before initiation of feeding was significantly reduced in group B when compared to group A [26.72[±3.68] vs [39.66[±4.7] and also there was significant reduction of hospitalization days in group B when compared to group A [3.78 [±1.25] vs [7.36[±1.28]. Conclusion: Inhalational salbutamol reduced duration of supplemental oxygen therapy, the duration of hospitalization and time before initiation of feeding, and no adverse effects were reported. Thus, inhaled salbutamol seems to be effective and safe in TTN.
format	article
author	Ahmed Salama Lotfy El-Seheimy Mohamed Elsamanoudy
author_facet	Ahmed Salama Lotfy El-Seheimy Mohamed Elsamanoudy
author_sort	Ahmed Salama
title	Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn
title_short	Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn
title_full	Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn
title_fullStr	Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn
title_full_unstemmed	Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn
title_sort	inhaled salbutamol for the treatment of transient tachypnea of the newborn
publisher	Al-Azhar University, Faculty of Medicine (Damietta)
publishDate	2020
url	https://doaj.org/article/09c70ed0e3ff40c9b7fae27b3e46ff95
work_keys_str_mv	AT ahmedsalama inhaledsalbutamolforthetreatmentoftransienttachypneaofthenewborn AT lotfyelseheimy inhaledsalbutamolforthetreatmentoftransienttachypneaofthenewborn AT mohamedelsamanoudy inhaledsalbutamolforthetreatmentoftransienttachypneaofthenewborn
_version_	1718392360023359488

Inhaled Salbutamol for the Treatment of Transient Tachypnea of the Newborn

Ejemplares similares